Onkologie. 2008:2(2):123-127

Výskyt nádorových onemocnění u pacientů po transplantaci srdce

Lenka, Hošková1, Ivan. Málek1, Mariana Podzimková, Mariana. Podzimková1, Jan Pirk1, Pavel. Trunečka2, Martin, Kment3
1 Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
2 Transplantcentrum, Institut klinické a experimentální medicíny, Praha
3 Patologicko-anatomické pracoviště, Institut klinické a experimentální medicíny, Praha

Úvod: Nádorová onemocnění se u pacientů po transplantaci srdce vyskytují 4–7× častěji než v běžné populaci a rychleji progredují. Cílem práce bylo zjistit výskyt nádorů v různě dlouhém období od transplantace a rozložení jednotlivých typů nádorů.

Metodika: Od ledna 1984 do prosince 2007 bylo v IKEM provedeno 670 transplantací srdce, z toho u 556 mužů a 114 žen. Základním onemocněním byla u 49 % kardiomyopatie, u 40 % ischemická choroba srdeční. Po transplantaci byli pacienti sledováni v pravidelných 3–4měsíčních intervalech, v prvním roce častěji. Diagnóza byla stanovena na základě klinických příznaků, odchylek v laboratorních nálezech a za pomoci zobrazovacích metod. Všem pacientům s nádorem byla upravena imunosupresivní léčba.

Published: August 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hošková L, Málek I, Podzimková M, Podzimková M, Pirk J, Trunečka P, Kment M. Výskyt nádorových onemocnění u pacientů po transplantaci srdce. Onkologie. 2008;2(2):123-127.
Download citation

References

  1. Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report - 2007. J Heart Lung Transplant. 2007; 26: 769-781. Go to original source... Go to PubMed...
  2. Garlicki M, Wierzbicki K, Przybylowski P et al. The incidence of malignancy in heart transplant recipients. Ann Transplant. 1998; 3: 41-47. Go to PubMed...
  3. Couetil JP, McGoldrick JP, Wallwork J, English TA. Malignant tumors after heart transplantation. J Heart Transplant. 1990; 9: 622-626.
  4. Penn I. Malignant neoplasia in the immunocompromised patient. In Cooper DKC, Miller LW, Pattersen GA (eds): The transplantation and replacement of thoracic organs. Hingham, MA: Kluwer Academic, 1996. Go to original source...
  5. Kauffman HM. The United Network for organ sharing position on using donors wiith primary central nervous system malignancies. Transplantation 2005; 79: 622-623. Go to original source... Go to PubMed...
  6. Rinaldi M, Pellegrini C, DÁrmini AM et al. Neoplastic disease after heart transplantation: single center experience. J Thor Cardiovasc Surg 2001; 19: 696-701. Go to original source... Go to PubMed...
  7. Hemmens VJ, Moore DE. Photochemical sensitisation by azathioprine and its metabolits: II. Azathioprine and nitroimidazole metabolites. Photochem Photobiol. 1986; 43: 257-262. Go to original source... Go to PubMed...
  8. Swinnen LJ, Costanzo-Nordin MR, Fischer SG et al. Increased incidence of lymphoproliferative disorder after immunosupression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723-1728. Go to original source... Go to PubMed...
  9. Euvrard S, Kanitakis J, Pouteil-Noble C et al. Comparative epidemiologic study of premaligmant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatos 1995; 33: 222-229. Go to original source... Go to PubMed...
  10. Kanitakis J, Euvrard S, Claudy A. Skin cancers in organ transplant recipients. J Am Acad Dermatol. 2006; 54: 1115. Go to original source... Go to PubMed...
  11. Veness MJ. Cardiac transplant-related cutaneous malignancies in an Australian recipients, Clinical Oncology 1998; 10: 194-147. Go to original source... Go to PubMed...
  12. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early withdrawal reduces the risk for cancer in adult renal transplantation J Am Nephrol. 2006; 17: 581-589. Go to original source... Go to PubMed...
  13. Mathew T, Kreis H, Friend P. Two-years incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449. Go to original source... Go to PubMed...
  14. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant. 2007; 26: 557-564. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.